Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : Inserm
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Favipiravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Communicable Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 06, 2023
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : Inserm
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Autologous Synovial Stem Cell
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of FF-31501 in Meniscus Tear Patients
Details : Human Autologous Synovial Stem Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Tibial Meniscus Injuries.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 21, 2023
Lead Product(s) : Human Autologous Synovial Stem Cell
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Appili Therapeutics
Deal Size : $1.0 million
Deal Type : Agreement
Details : As part of the agreement, FFTC will receive direct access to PRESECO data in support of local regulatory submissions in Japan. PRESECO is investigating the safety and efficacy of Avigan/Reeqonus in the early treatment outpatient setting for adults infect...
Product Name : Avigan
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 20, 2021
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Appili Therapeutics
Deal Size : $1.0 million
Deal Type : Agreement
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The efficacy primary endpoint is time to negative conversion of detectable SARS-CoV 2 viral RNA in the RT-PCR assays, and to alleviation of symptoms (body temperature, oxygen saturation and chest images).
Product Name : Avigan
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 23, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Dr. Reddy\'s Laboratories
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the partnership, Dr. Reddy’s will have exclusive rights for development, selling and distribution of Avigan® in India. Further, FUJIFILM would receive an upfront license fee and royalties on sales from Dr. Reddy’s and GRA.
Product Name : Avigan
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 01, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Dr. Reddy\'s Laboratories
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Dr. Reddy\'s Laboratories
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Fujifilm to Partner with Dr Reddy's to Sell Avigan Overseas as Covid-19 Treatment
Details : The agreement provides for Fujifilm Toyama Chemical to grant Dr. Reddy's and Dubai-based Global Response Aid the right to develop, make and sell Avigan overseas and get a lump-sum license fee and royalties on sales.
Product Name : Avigan
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 01, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Dr. Reddy\'s Laboratories
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Appili Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Details : Appili Therapeutics to sponsor first clinical program in the world designed to assess the use of FUJIFILM Toyama Chemical’s favipiravir for COVID-19 as prophylaxis for outbreak control.
Product Name : Avigan
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 11, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Appili Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Chinese official says Fujifilm’s Favipiravir could treat Covid-19
Details : Patients who were given the medicine in Shenzhen turned negative for the virus after a median of four days after becoming positive compared to theose who were not treated with the drug.
Product Name : Avigan
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 18, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : T-817MA is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cognitive Dysfunction.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 09, 2019
Lead Product(s) : T-817MA
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Celerion
Deal Size : Inapplicable
Deal Type : Inapplicable
PK Study of T-817 in Subjects With Hepatic Impairment
Details : T-817MA is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Failure.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 26, 2016
Lead Product(s) : T-817MA
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Celerion
Deal Size : Inapplicable
Deal Type : Inapplicable